Gara Jalqabaatti › Kansaar Onnee Triple-Negative › Alabama
Qorannoo klinikaalii Kansaar Onnee Triple-Negative Alabama keessatti
Qorannoo 11 Kansaar Onnee Triple-Negative f Alabama keessatti hirmaatuu jiru.
Magaalota Alabama keessatti
Takkalaa qorannoo (Ingiliffa)
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- Dothan Hematology & Oncology, Dothan
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT07189871PRE-ISPY Phase I/II Oncology Platform Program
- The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT05868226A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- USA Mitchell Cancer Institute ( Site 0090), Mobile
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06841354Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Infirmary Cancer Care ( Site 0001), Mobile
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06393374A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- University of Alabama at Birmingham, Birmingham
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 23-Ful-2026 · NCT06618287Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Alabama Oncology, Birmingham
- Clearview Cancer Institute, Huntsville
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 09-Ful-2026 · NCT05633654Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Birmingham Hematology Associates, Birmingham
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 hanga 99 · Saalaa hunda · Haaromfame 03-Ful-2026 · NCT07211178Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)
- UAB, Birmingham
Namoota walitti qabaa jiraSadarkaa jalqabaa 1
Umuriin 18 hanga 75 · Dubartoota · Haaromfame 17-Hag-2026 · NCT04861077Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Uni of Alabama at Birmingham, Birmingham
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 100 · Saalaa hunda · Haaromfame 29-Ado-2026 · NCT06562192A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- University of Alabama at Birmingham, Birmingham
- University of Alabama at Birmingham, IDS Pharmacy, Birmingham
- University of Alabama at Birmingham, Birmingham
- fi 1 dabalataa
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ado-2026 · NCT05208762I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- University of Alabama at Birmingham, Birmingham
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 06-Cam-2026 · NCT01042379Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.